ViraTherapeutics scores €3.6m series-A

The round also included an investment from Austria's public bank, Austria Wirtschaftsservice, through its venture capital initiative.

The Boehringer Ingelheim Venture fund was launched in 2010 to back therapeutics-focused biotech companies. The vehicle manages €100m and currently has 15 businesses in its portfolio.

EMBL Ventures is an independent venture capital investor managing €68m across two funds. It exclusively focuses on life sciences investments.

Company
Founded in 2013 as a spinout of the Medical University of Innsbruck, ViraTherapeutics develops oncolytic cancer vaccines based on a chimeric virus. It currently employs six people.

People
Detlev Mennerich and Jan Adams worked on the deal for BIVF and EMBL, respectively. They both joined the company's advisory board.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Early-stage
• Healthcare
• Germany